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Great progress has been made with protocols for the differentiation and func-
tional application of hPSC-cardiomyocytes (hPSC-CMs) in recent years; how-
ever, the cryopreservation and recovery of hPSC-CMs still presents challenges
and few reports describe in detail the protocols and general workflow. In order
to facilitate cryopreservation and recovery of hPSC-CMs for a wide range of
applications, we provide detailed information and step-by-step protocols. The
protocols are simple and use common reagents. They are comprised of a fast
dissociation, cryopreservation using standard equipment, and gentle recovery
following thawing. We discuss various features of the protocols, as well as their
utilization in the context of common hPSC-CM differentiation and application
workflows. Finally, we compare two proprietary and two common in-house
formulations of cryopreservation media used for hPSC-CMs, and despite dif-
ferences in their price and composition find broadly similar recovery rates and
cellular function after thawing. © 2019 The Authors.
Basic Protocol 1: Dissociation and cryopreservation of hPSC-CMs
Basic Protocol 2: Thawing and recovery of cryogenically frozen hPSC-CMs
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INTRODUCTION
The usability of human pluripotent stem cell-derived cardiomyocytes (hPSC-CMs) for
applications within regenerative medicine, toxicology screening, and disease modelling,
depends heavily on efficient reproducible bioprocesses. One of these bioprocesses is
hPSC-CM cryopreservation, as it enables the generation, transportation, and application
of large differentiation batches, which simplifies supply chains and should reduce vari-
ability and cost (Dunn & Palecek, 2018; Preininger, Singh, & Xu, 2016). Even on a
small scale, reliable freezing and thawing of hPSC-CM batches greatly facilitates project
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Figure 1 Overview of general hPSC-CM differentiation and handling workflow. Schematic and representative
microscopy images of an hPSC-CM differentiation protocol in an adherent monolayer. Following an optional CM
enrichment around days 9-12, and after at least 2 days recovery in normal CM Maintenance medium, hPSC-
CMs can be dissociated and cryopreserved. They can subsequently be thawed and re-plated at a desired
density for downstream application, e.g., analysis by multi electrode array (MEA). Bars = 250 μm.
management and experimental reproducibility. However, hPSC-CMs appear to be less
robust towards freeze-thawing than many other cell types, with reported viable recovery
rates varying greatly from 50% to 84% (Burridge, Holmström, & Wu, 2015; Chen et al.,
2015; van den Brink et al., 2020; Xu et al., 2011). Over nearly a decade, various options
in terms of protocols and reagents for cryopreservation have appeared, and although a
few papers provide some detail or investigate the functional effects of cryopreservation
on hPSC-CMs, there is not yet a consensus with regards to workflow or best practice. For
more in-depth discussion please see Background Information and Understanding Results.
In this article, we outline a simple workflow for the step-by-step dissociation, cryopreser-
vation, and functional recovery of hPSC-CMs that have been differentiated in adherent
monolayer culture (Fig. 1). This can be performed without specialized equipment and
should be applicable to many hPSC-CM differentiation protocols and downstream appli-
cations (see Strategic Planning). We provide analytical data, as well as a comparison of
four common hPSC-CM freezing medium (Table 1; see Basic Protocol 2 “Sample data”).
The protocols are as follows:
• Dissociation and cryopreservation of hPSC-CMs (Fig. 2)–includes sample data of
effect of differentiation day on dissociation and freezing (Fig. 3)
• Thawing and recovery of cryogenically frozen hPSC-CMs (Fig. 4)–includes sample
data of functional recovery and comparison of freezing media (Fig. 5)
STRATEGIC PLANNING
The simple workflow for cryopreservation and recovery described here is ideally inte-
grated within the wider context of monolayer differentiation, quality control (QC), and
functional application of hPSC-CMs. The most commonly used differentiation proto-
cols including the one used in experiments here are based on small molecule inhibition
of WNT signaling, which may also include a CM enrichment step (Fig. 1) (Lian et al.,
2012; Tohyama et al., 2013). This cryopreservation workflow should work comparably
well with hPSC-CMs generated using other similar differentiation protocols or kits (see
Background Information). For generating batches of hPSC-CMs for cryopreservation,
we would recommend differentiation of 1-4 multi-well plates, usually 6- or 12-well, and
find that this can generate up to 2.5 × 108 cells. We and others have found several key
parameters affecting hPSC-CM differentiation efficiency and yield. Batch variability inMiller et al.
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Table 1 Overview of Selected Media for Cryopreservation of hPSC-CMsa
Freezing medium Cost (100 ml)b Component features Recommended protocolc
hPSC-CM
referencesd





None available Chen et al. (2015);
Gerbin, Yang,
Murry, & Coulombe
(2015); Liu et al.
(2018); Xu et al.
(2011)
FBS-DMSO 10% 121€ NA None available Breckwoldt et al.
(2017); Burridge et
al. (2015)
KSR-DMSO 10% 69€ Defined except
for lipid rich-BSA








Freezing density of 0.5 ×










aAll media listed contain 10% DMSO as cryoprotective agent (CPA); see Reagents and Solutions.
bList price in Germany as of April 2020.
cWhere manufacturer instructions for hPSC-CMs are available and differ from this article.
dSelection of primary research articles using indicated media, not including all subsequent derivative articles–see Background Information and Under-
standing Results for further discussion.
certain reagents, particularly B-27 and CHIR, may have significant impacts on differen-
tiation. For several of our hPSC lines, 6 μM CHIR for the first days of differentiation
works well, but across many lines and published protocols the range is 6-12 μM, and an
optimal concentration often has to be determined individually for hPSC lines and spe-
cific protocols. Cell density at the start of differentiation is also very important, with
∼80% being regarded as ideal (Allen_Institute, 2018; Burridge et al., 2014; D’Antonio-
Chronowska et al., 2019; Kempf et al., 2016).
Before freezing hPSC-CMs, it is important to roughly estimate the expected cell num-
ber before dissociation and have an adequate amount of medium and number of labelled
cryovials and cryostorage boxes prepared before starting. As a guideline, we generate
an average of 4.01 ±1.44 × 107 cells per 6-well plate (n = 5, ±SD). Similarly before
thawing and re-plating hPSC-CMs, it is important to calculate how many cells are re-
quired and in what format for their downstream application and prepare sufficient media
and coated plates beforehand. See Basic Protocol 2 and Table 2 for more information on
coating and plating densities.
In order to determine the cell number before freezing and after thawing, cell counting in-
cluding live/dead exclusion must be performed. There are various approaches and equip-
ment available for this, which will tend to generate slightly different numbers relative
to each other. It is advisable to use just one method across experiments so that numbers
remain consistent. In this article we have used an automated cell counter and trypan blue
exclusion; however, manual counting using a hemacytometer will work equally well,
notwithstanding variability between individual users. Miller et al.
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6-well 9.5 1.5 ml 15-30 3 ml
12-well 3.8 0.6 ml 5-10 1 ml
24-well 1.9 0.3 ml 2.5-5.0 0.5 ml
48-well 1 0.2 ml 1.0-2.0 0.3 ml
96-well 0.32 0.06 ml 0.3-0.5 0.1 ml
384-well 0.056 0.03 ml 0.04-0.08 0.05 ml
8-well chamber slide 0.78 0.2 ml 0.8-1.2 0.25 ml
48-well MEAb — 0.008 ml droplet 0.3-0.5 0.3 ml
aPrepare Geltrex-coated plates on the day or up to 2 weeks in advance according to manufacturer’s instructions (Thermo
Fisher Scientific, 2013). Suggested densities should generate a fairly complete monolayer of cells 5 days following re-
covery from thawing (Fig. 5B). A range is indicated to allow for optimization, the lower figure being most appropriate
following optimally recovered cryogenically frozen or freshly dissociated hPSC-CMs.
bCoating of wells and subsequent plating of hPSC-CMs in Axion Biosystems Cytoview or E-Stim+ plates must be done
the same day, and may only cover the electrodes in the center of the well, hence both coating and cell plating must be
done as successive 8 μl droplets, with maintenance medium topped up after 1.5-2 hr. Geltrex at half the normal dilution
was found to work well. For more information refer to https://www.axionbiosystems.com/resources.
BASIC
PROTOCOL 1
DISSOCIATION AND CRYOPRESERVATION OF hPSC-CMs
This protocol describes the careful dissociation and cryopreservation of hPSC-CMs
(Fig. 2). There are several critical aspects to preserving the viability of hPSC-CMs dur-
ing this process. The first is effective dissociation without degradation of the cells. This
presents a challenge as often differentiating hPSC-CM monolayer cultures have a high
cell density (Fig. 3A), and tend to increase the amount of extra cellular matrix proteins
they secrete and cell-cell junctions they generate, which all need to be digested. The
most often cited approach uses fast but powerful enzymatic dissociation, which is what
is described here. An alternative is more slow but gentle dissociation, requiring differ-
ent reagents and protocol (see Background Information). The next important aspect is
gentle handling of the cells. Slow regular trituration generating a minimal amount of
effervescence and sheer stress is strongly advised. Finally, slow but steady cooling of
−1°C/min and protection against intracellular ice formation via a cryoprotective agent
(CPA) is important for all conventional cell cryopreservation. Here this is handled via
proprietary Mr. Frosty
TM
cryopreservation boxes; however, other products and even con-
trolled rate freezing machines such as ViaFreeze
TM
should work well. The impact of
different cryopreservation media is discussed in Basic Protocol 2 and Understanding
Results.
Materials
hPSC-CMs in 6- or 12-well plates (see Fig. 1 and Strategic Planning)
CM Freezing medium (see recipe)
CM Suspension medium (see recipe)
DPBS without Ca2+/Mg2+ (PBS-) (e.g., Thermo Fisher, cat. no. 14190144)
TrypLE Select, 10× (Thermo Fisher, cat. no. A1217701)
Trypan blue solution (e.g., Sigma Aldrich, cat. no. T8154)
Cryogenic storage boxes (e.g., Mr Frosty
TM
, Thermo Fisher, cat. no. 5100-0001)
37°C, 5% CO2 incubator
15- and 50-ml Falcon
TM
polypropylene tubes (e.g., Corning, cat. nos. 352096 and
352070)Miller et al.
4 of 18
Current Protocols in Stem Cell Biology
Figure 2 Schematic of hPSC-CM dissociation and freezing (Basic Protocol 1).1.Dissociate hPSC-CMs by incubating
with 10× TrypLE and gently pipetting; 2. Transfer hPSC-CMs to CM Suspension medium and centrifuge; 3.Resuspend
hPSC-CMs, count and centrifuge again; 4Resuspend hPSC-CMs in CM Freezing medium; 5Transfer 0.5-1 ml cell
suspension/cryovial, add to cooled cryostorage boxes and place overnight at −80°C before transferring to liquid
N2. Lower panel: Phase-contrast microscopy showing time course for dissociation of hPSC-CMs using TrypLE 10×,
bar = 250 μm.
Microscope (e.g. Leica DMi1)
1000-μl manual pipette plus 1000-μl filter tips (e.g., Eppendorf, 613-0866;
Biozym, cat. no. VT0270)
Centrifuge (e.g., Eppendorf 5810R, Thermo Fisher, cat. no. 10012724)
Pipette gun and 5- to 10-ml stripettes (e.g., INTEGRA Biosciences, cat. no.
156400; Sarstedt, 86.1253.001; Sarstedt86.1254.001)
Countess
TM
II automated cell counter (Thermo Fisher, cat. no. AMQAX1000)
Countess
TM
cell counting slides (Thermo Fisher, cat. no. C10228)
Cryovials (e.g., CryzoTraq 2 ml, Ziath, cat. no. 590010)
NOTE: Perform all centrifugation steps at room temperature.
NOTE: The following protocol steps are based on the dissociation and cryopreservation
of 2 × 6-well plates of hPSC-CMs at around day 14 of differentiation (Fig. 3A), which
would generate approximately 6–10 × 107 cells. Dissociation of the two individual plates
is slightly staggered to reduce disparity in 10× TrypLE incubation times.
Miller et al.
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Figure 3 Schematic of hPSC-CM thawing and re-plating (Basic Protocol 2).1.Quick thaw of hPSC-CMs in water bath;
2.Transfer thawed hPSC-CMs into 50-ml Falcon tube and slow dropwise addition of 1 ml CM Suspension medium,
swirling in between; 3. Slow dropwise addition of 5 ml CM Suspension medium, swirling in between, and then transfer
into 15-ml Falcon tube; 4. Centrifugation and resuspension in CM Suspension medium; 5. Cell count and adjustment
of volume to desired cell density; 6. Addition to pre-coated culture plates and incubation.
1. Ensure a sufficient amount of the following reagents and equipment are pre-cooled
by placing them for 30 to 60 min at 4°C before starting (if not already stored there):
cryostorage boxes, CM Freezing medium.
2. Ensure a sufficient amount of the following reagents are brought to room temperature
for 30-60 min before starting: CM Suspension medium, 10× TrypLE, PBS-.
3. Aspirate culture medium from hPSC-CMs, wash wells once with 1.5 ml PBS- each,
and aspirate.
4. Add 1 ml of 10× TrypLE to each well of the first culture plate of hPSC-CMs and
incubate at 37°C, 5% CO2 (Fig. 2_1).
NOTE: If hPSC-CM cell density is significantly lower than that shown in Figure 3A, 10×
TrypLE can be slightly diluted to 5-8× using PBS-. See Troubleshooting.
5. After 2 min, add 1 ml of 10× TrypLE to each well of the second culture plate and
incubate at 37°C, 5% CO2.
NOTE: If a cell shaker is available in the incubator, place plates on this at a speed of
50-70 rpm, and reduce total incubation time by 1-2 min. See Troubleshooting.
6. Prepare a 50-ml Falcon tube for collection of cells, with 1.5 ml CM Suspension
medium added per well.
NOTE: For 2 × 6-well plates, add 18 ml.
7. After 6-7 min incubation, remove each plate from incubator to check under the mi-
croscope for cell rounding and loosening (Fig. 2, lower panel).Miller et al.
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8. Replace cells in incubator and check again after 1-4 min, until almost the whole cul-
ture has rounded into individual cells and clusters, but with only a few free-floating
cells or small cell clusters detached from the culture plate surface (Fig. 2, lower
panel).
CRITICAL STEP: Judging the period of time for dissociation is a critical parameter.
Different hPSC lines and differentiation protocols cause variability in the cell density
and adherence; hence, total dissociation time will generally vary within the range of
8-12 min. See Troubleshooting.
9. Remove cells from incubator and using a 1000-μl pipette, gently triturate cells in
each well, tilting the plate towards you and pipetting around the far side of the well in
a semi-circular motion 3-4 times, then tilting the plate away from you and pipetting
around the near side of the well in a semi-circular motion 3-4 times (Fig. 2, lower
panel).
CRITICAL STEP: Steady but gentle pipetting at this stage is crucial to dissociate the cells
fully but avoid effervescence and shear stress leading to cell degradation and clumping
later on. See Troubleshooting.
10. Carefully transfer the TrypLE-cell suspension into the 50-ml collection Falcon con-
taining CM Suspension medium.
NOTE: Albumin and other factors in CM Suspension medium partially quench the pro-
tease activity of 10× TrypLE.
11. Add an additional 1 ml fresh CM suspension medium to each well and using a
1000-μl pipette gently wash and elute final remaining cells, adding them to the 50-
ml collection Falcon.
Counting and Freezing
12. Centrifuge the cells for 3 min at 200 × g, (Fig. 2_2).
NOTE: We have found that lower centrifugation speeds usually pellet cells as effectively
as higher speeds, and importantly help to reduce clumping of hPSC-CMs. If significant
amounts of cells are still in suspension following centrifugation, perform a second cen-
trifugation for 2-3 min at 300 × g.
13. Aspirate the supernatant and very gently flick the bottom of the Falcon tube to help
disperse the large cell pellet.
14. Carefully add 1 ml fresh CM Suspension medium directly to the cells at the bottom
of the tube using a 1000-μl pipette, and gently pipette up and down several times.
15. Add an additional 9 ml CM Suspension medium to the cells using a stripette
(Fig. 2_3).
NOTE: This step is important as a wash step to remove excess protease, as well as cellular
debris, which allows a more accurate viable cell count. If significant cell clumping has
occurred, it can also be more easily identified at this stage. See Troubleshooting.
16. Invert to mix, remove a 10-20-μl sample of cells and perform a viable cell count
using Trypan Blue (Fig. 3B).
NOTE: For Countess II, use default settings, and perform at least one and ideally two
cell counts on each side of a counting chamber.
NOTE: It is advisable to extract any cells required at this stage for re-plating fresh without
cryopreservation, or sampling, e.g., for QC by flow cytometry (Fig. 3D).
17. Centrifuge again for 3 min at 200 × g.
Miller et al.
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18. Aspirate the supernatant and resuspend hPSC-CMs in cooled CM Freezing medium
to a density of 2-10 × 106 cells/ml, pipetting gently to mix (Fig. 2_4).
NOTE: For discussion on cell freezing density see Background Information.
19. Pipette 0.5-1 ml hPSC-CM cell suspension into cryovials and place in cooled cryos-
torage boxes (Fig. 2_5).
20. Place cryostorage boxes at −80°C for at least 4 hr (generally overnight) before trans-
ferring cryovials to the vapor phase of liquid N2 for long-term storage.
Sample data
Following cardiac differentiation of hPSCs (Fig. 1), we investigated the effect of dissoci-
ation and cryopreservation on hPSC-CMs. We found that the time point (differentiation
day) for initial (first) dissociation may make a difference to the viability of the hPSC-
CMs. In our hands, the viability of hPSC-CMs tends to decrease with a later time point
for initial dissociation, day 14 tending to be better than day 21 (Fig. 3B), with a mean
viability of 84% ±2.9 (SEM). Where possible we would therefore suggest an initial dis-
sociation at an earlier time point i.e., around day 14 of differentiation (see Background
Information and Understanding Results). However, dissociation and freezing of hPSC-
CMs at later time points additionally to an initial dissociation at an earlier time point does
not significantly affect the recovery of cells (Fig. 3C). As a general workflow, we would
also recommend taking a sample of ∼1 × 106 cells for QC by flow cytometry following
dissociation (Fig. 3D) (e.g., see Berg Luecke, Waas, & Gundry, 2019). Together these
data and simple protocol should facilitate the preparation and handling of hPSC-CMs for
dissociation and cryopreservation at specified time points during differentiation.
BASIC
PROTOCOL 2
THAWING AND RECOVERY OF CRYOGENICALLY FROZEN hPSC-CMs
Similar to many other cell types, maintaining good recovery and viability of hPSC-CMs
during thawing is dependent on a controlled but fast thaw and a gentle resuspension in
culture medium (Fig. 4). For hPSC-CMs, slow dropwise resuspension using a relevant
culture medium is particularly important for avoiding osmotic shock and maintaining
viability (see Background Information).
Cryopreserved cells should be kept frozen until all downstream steps for thawing and re-
covery have been prepared first. Most importantly this includes coated cell culture plates
for the downstream application of the cells. Differentiated hPSC-CMs can be re-plated at
specified densities onto different types of cell culture plate (Table 2) coated with various
forms of extra cellular matrix (ECM). Re-plating can be done either immediately follow-
ing dissociation or after thawing from cryopreservation. In our hands, Geltrex is largely
equivalent to Matrigel and works well for applications where a complete monolayer is
desired, including on glass and plastic bottom plates, and those containing electrodes.
Fibronectin is also widely used, especially where a lower density of cells on glass bot-
tom plates is required, e.g., for patch clamping. Other ECMs such as Laminin-221/211
are known to work.
Materials
Geltrex (Thermo Fisher, cat. no. A1413302)
DMEM/F-12 (Thermo Fisher, cat. no. 11330032)
CM Suspension medium (see recipe)
Dry ice or liquid nitrogen
Cryovials of cryopreserved hPSC-CMs (see Basic Protocol 1)
RevitaCell
TM
Supplement 100× (Thermo Fisher, cat. no. A2644501)
CM Maintenance medium (see recipe)
Trypan blue solution (e.g., Sigma Aldrich, cat. no. T8154)Miller et al.
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Figure 4 Effects of dissociation and cryopreservation time points on hPSC-CMs. (A) Phase-contrast microscopy
of hPSC-CM monolayers at day 14 or 21 of differentiation prior to initial dissociation. Bar = 100 μm. (B) Viability
staining with trypan blue following initial dissociation of hPSC-CMs at different time points during differentiation.
Points represent individual differentiation experiments from three different hPSC lines (represented by circles,
triangles or squares), except for red, blue, and black, which are corresponding experiments dissociated at different
time points. Regression analysis showed R2 = 0.45, with a coefficient y = −0.016× +107 (p = 0.048), indicating
that around half the change in viability is due to day of dissociation. (C) Cell recovery following freezing and thawing
of hPSC-CMs at different time points during differentiation. hPSC-CMs had been dissociated and re-plated at an
earlier time point (∼days 12-16) and subsequently dissociated a second time before freezing at 3 × 106 cells/vial
using CryoStor CS10. Mean recovery = 1.8 × 106 ±0.13 cells/vial ±SEM (60%), p = 0.22 (one-way ANOVA). (D)
Representative flow cytometry plot and mean CM marker expression in dissociated fixed hPSC-CMs at day 13-15 of
differentiation. Inset shows isotype control staining. hPSC-CMs from this differentiation batch were cryopreserved
using different cryopreservation media, see Figure 5C. Mean TNNT2 expression at days 13-15 across multiple
differentiation batches and lines was 94.3% ± 2.7 (n = 5, ±SEM).
Multi-well culture plates (e.g., 24-well, Greiner Bio-One, cat. no. 662160)
Parafilm® M sealing film (Sigma, cat. no. P6543-1EA)
Isothermal ice bucket (e.g., Fisherbrand
TM
Polyurethane Ice Buckets, Fisher
Scientific, cat. no. 11324085)
Water bath (e.g., VWR, cat. no. 462-0554)
1000-μl manual pipette plus 1000-μl filter tips (e.g., Eppendorf, cat. no. 613-0866;
Biozym, cat. no. VT0270)
15- and 50-ml Falcon
TM
polypropylene tubes (e.g., Corning, cat. nos. 352096 and
352070)
Pipette gun and 5-10-ml stripettes (e.g., INTEGRA Biosciences, cat. no. 156400;
Sarstedt, 86.1253.001; Sarstedt86.1254.001)
Centrifuge (e.g., Eppendorf 5810R, Thermo Fisher, cat. no. 10012724)
37°C, 5% CO2 incubator
Countess
TM
II automated cell counter (Thermo Fisher, cat. no. AMQAX1000)
Countess
TM
cell counting slides (Thermo Fisher, cat. no. C10228)
Miller et al.
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Table 3 Volumes of CM Suspension Medium Required for the Resuspension of hPSC-CMs Im-
mediately After Thawinga
No. cryovials Volume frozen cells Volume initial resuspension Top up volume
1 0.5-1 ml 1 ml 5 ml
2 1-2 ml 2 ml 8 ml
aThe volume of initial resuspension is to be added dropwise using a 1000 pipette-μl, with the top up volume subsequently
added dropwise using a 5-10-ml stripette.
NOTE: Perform all centrifugation steps at room temperature.
NOTE: Follow safety guidance when handling cryogenically frozen material and liquid
N2 storage containers.
NOTE: The following protocol steps are intended for defrosting 1× or simultaneously
2× cryovials of hPSC-CMs pooled into one Falcon tube (see Table 3).
Thawing and Resuspension
1. Dilute Geltrex using DMEM/F12 and prepare Geltrex-coated plates according to
manufacturer’s instructions (Thermo Fisher Scientific, 2013), ensuring adequate
numbers of desired wells/plates are incubated at 37°C 60 min before thawing cells
(see Table 2).
NOTE: Plates can be prepared up to 2 weeks beforehand and stored at 4°C after sealing
with Parafilm.
NOTE: Ensure no area of the culture surface is allowed to dry out following Geltrex
coating or during storage.
2. Allow an adequate volume of CM Suspension medium to reach room temperature
for 30-60 min before thawing cells (Tables 2 and 3).
3. Using dry ice or liquid nitrogen, collect cryovial(s) of cryopreserved hPSC-CMs
from liquid N2 and bring to cell culture.
4. Perform a quick thaw in a 37°C water bath. Occasionally gently swirl tubes in the
bath, avoiding immersion above the level of the cap. Continue until about 90% de-
frosted (Fig. 4_1).
5. Sterilize the tube exterior before taking into laminar flow hood e.g., by wiping with
70% ethanol solution.
6. Using a 1000-μl pipette with 1000-μl pipette tip, remove cells from cryovial(s) and
gently pipette into the bottom of a 50-ml conical Falcon tube.
NOTE: Check the lids of cryovials as some models can retain large droplets of medium.
7. Using a fresh 1-ml pipette, add 1 ml CM Suspension medium to the cryovial to
recover any last microliters of leftover cells.
NOTE: If defrosting 2× vials, pipette the same 1 ml of CM Suspension medium from one
vial into the other.
8. Using the same pipette tip, take up the 1 ml of CM Suspension medium now in the
cryovial.
9. Dropwise and slowly, add the recovered 1 ml of CM Suspension medium into the
50-ml Falcon tube, aiming for about 1-2 drops every 3-5 s, gently swirling between
(Fig. 4_2).
CRITICAL: Slow resuspension of hPSC-CMs is crucial to avoid osmotic shock.
Miller et al.
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NOTE: If thawing 2× cryovials, repeat this dropwise addition of 1 ml medium to the
Falcon again (Table 3).
10. Using a stripette and pipette gun, add an additional 5 ml CM Suspension medium to
the cells dropwise and slowly, again aiming for several drops every 3-5 s, swirling
between (Fig. 4_3).
NOTE: If thawing 2× cryovials, an additional 8 ml rather than 5 ml should be added
(Table 3).
11. Transfer the cell suspension into a 15-ml Falcon tube.
Counting and Replating
12. Centrifuge for 3 min at 300 × g, and aspirate the supernatant (Fig. 4_4).
13. Gently resuspend the cell pellet in half the amount of CM Suspension medium +
RevitaCell (1% v/v) corresponding to the cell density/number of wells desired (see
Table 2).
NOTE: This allows precise adjustment of cell density later, since the recovery of cells
from frozen is 50%-70% (Fig. 3C; Fig. 5A)
NOTE: If using a different kind of medium for general hPSC-CM maintenance, it may
be a suitable alternative for CM Suspension medium from this point provided RevitaCell
or another kind of anti-apoptosis inhibitor is added prior to plating, see Background
Information.
14. Perform a cell count including trypan blue live/dead staining using Countess II and
counting slides, followed by an adjustment of the volume using CM Suspension
medium + RevitaCell (1% v/v) to the desired cell density (Fig. 4_5).
15. Remove Geltrex coating solution from intended culture plates and add the cell sus-
pension to Geltrex-coated wells (Fig. 4_6).
NOTE: For most hPSC-CM applications, plates should be gently rocked side to side then
back and forth at this point to distribute the cells evenly across the well; however, for
MEA plates this is not advised (Table 2).
16. Incubate the cells at 37°C, 5% CO2.
17. The next day, change medium to CM Maintenance medium (Table 2).
18. Continue culturing hPSC-CMs in CM Maintenance medium for at least 5 days
before use in downstream applications (Fig. 5B-E), changing medium every 2 to
3 days.
Sample data
By following Basic Protocols 1 and 2 described here, a hPSC-CM recovery rate of be-
tween 50% and 70% can generally be expected (Fig. 3C; Fig. 5A). We investigated po-
tential differences between certain cryopreservation media (Table 1). In our hands, dif-
ferent media appear to have only marginal effects on hPSC-CM viability and recovery.
An exhaustive study would be required; however, in a limited study we find that viability
and recovery upon thawing are comparable between four common freezing media (Fig.
5A), with a coupled spontaneously contracting monolayer exhibiting typical hPSC-CM
morphology forming after 5 days (Fig. 5B), and similar levels of CM marker expression
(Fig. 5C). We further investigated the three more chemically defined freezing media (Ta-
ble 1) and found recovered hPSC-CMs to have a similar intracellular morphology and
expression of cytoskeletal components and cardiac markers (Fig. 5D), as well as a compa-
rable electrophysiological profile (Fig. 5E). These data show that the workflow outlined
here in combination with potentially any of the four media tested can provide effective Miller et al.
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Figure 5 Comparison of hPSC-CM viability, recovery, marker expression, and electrophysiological function following
thawing from different cryopreservation media. (A) Viability and recovery of thawed hPSC-CMs frozen at differentiation
day 13 in 1 ml of cryopreservation medium at 2 × 106 cells/vial. N = 1× differentiation experiment with 3× vials per con-
dition, error bars ±SD. (B) Phase-contrast microscopy of hPSC-CMs one or 5 days following thawing. Bar = 100 μm. (C)
Representative flow cytometry plots and mean CM marker expression in dissociated fixed hPSC-CMs 7 days following
thawing from different cryopreservation media. Negative control used was undifferentiated hPSCs. Differentiation exper-
iments using two different lines BIHi005-A (striped) and BIHi050-A (block) are shown, N = 3× vials per line/condition,
error bars ±SD. (D) Immunofluorescence microscopy of hPSC-CMs fixed and immunostained 5 days following thawing
from different cryopreservation media. Blue nuclear counterstain was performed using DAPI. Bar = 100 μm. (E) Analysis
of hPSC-CM field potential (FP) using Axion Biosystems MEA and CytoView 48-well plate 5 days following thawing from
different cryopreservation media. After recording baseline spontaneous contraction, 1 μM isoprenaline or equivalent ve-
hicle was added and contraction analyzed. Correction of FP duration was done using Fridericia’s formula (cFPD). N =
1× cryovial across 4× wells per cryopreservation medium, subsequently divided into 2× wells each for vehicle or drug,
error bars ±SD.
cryopreservation and functional recovery of hPSC-CMs. Please see Background Infor-





CS10 (Stem Cell Technologies, cat. no. 07930)
• FBS/10% DMSO: –Fetal bovine serum (FBS) heat-inactivated (Thermo Fisher, cat.
no. 16140071); Dimethyl sulfoxide (DMSO; Sigma-Aldrich, cat. no. D2650). It is
recommended to defrost stock FBS and divide into 9- or 36-ml aliquots and freeze
for up to 3 months at −20°C. Defrost a 9- or 36-ml FBS aliquot until it reaches
room temperature, and then add 1 or 4 ml DMSO (10% v/v) and invert to mix.
Store complete medium for up to 2 weeks at 4°C.
• KSR/10% DMSO: –It is recommended to defrost stock KSR and divide into 9- or
36-ml aliquots and freeze for up to 3 months at −20°C. Defrost a 9- or 36-ml KSR
aliquot until it reaches room temperature, and then add 1 or 4 ml DMSO (10% v/v)
and invert to mix. Store complete medium for up to 2 weeks at 4°C.
Miller et al.
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• STEMdiff
TM
Cardiomyocyte Freezing Medium (Stem Cell Technologies, cat. no.
05030).
CM Maintenance medium
Add 10 ml B-27 supplement (Thermo Fisher, cat. no. 17504044) to 490 ml RPMI
basal medium (Thermo Fisher, at. no. 11875-093) (2% v/v) and invert to mix. Alter-
natively, for less frequent use, defrost and divide 10 ml of B-27 supplement into 1-ml
aliquots and freeze for up to 3 months at −20°C, and then defrost a 1-ml aliquot and
add to 49 ml RPMI basal medium. Store complete medium up to 2 weeks at 4°C.
CM Suspension medium
Add 4 ml KnockOut
TM
serum replacement (KSR; Thermo Fisher, cat. no. 10828028)
to 36 ml CM Maintenance medium (10% v/v; see recipe) and invert to mix. Store
complete medium up to 2 weeks at 4°C.
COMMENTARY
Background Information
Two fundamental aspects of hPSC-CM
bioprocessing for downstream applications
are efficient reproducible differentiation and
viable cryopreservation. In general, and par-
ticularly for diverse smaller scale research ap-
plications of hPSC-CMs, the simplicity of the
workflows for these processes greatly facili-
tates their utilization. While simple hPSC-CM
differentiation protocols have become much
more precise and efficient (Denning et al.,
2016), there is a slight dearth of improvement
and understanding with regards to cryop-
reservation. The review by Preininger and
colleagues is a helpful navigator (Preininger
et al., 2016). Among the publications that do
openly report or specifically investigate cry-
opreservation of hPSC-CMs, as noted in the
Introduction, there are widely varying rates of
recovery (Burridge et al., 2015; Chen et al.,
2015; van den Brink et al., 2020; Xu et al.,
2011), and anecdotally recovery rates tend
to be lower. Early reports also cryopreserved
hPSC-CMs that had been differentiated at a
lower purity and consistency (Xu et al., 2011);
hence, their methods and recovery rates may
not be wholly applicable now. A high recovery
rate of 84% ±5.2 is reported by Chen and
colleagues; however, hPSC-CMs were differ-
entiated as 3D clusters in stir tank bioreactors
and dissociated using a two-step protocol (see
below; Chen et al., 2015). Few studies address
the potential effects of cryopreservation on
hPSC-CMs with detailed analysis, and to our
knowledge there are no in-depth comparisons
of cryopreservation media. One report by
Brink and colleagues investigates the effect
of cryopreservation on the electrophysiology
and transcripts of two hPSC lines (van den
Brink et al., 2020). Interestingly, they find that
following cryopreservation there is mostly no
effect on key electrophysiological parameters,
although one hPSC line did exhibit slight
increases in ventricular, ion channel, and
cytoskeletal marker expression compared
with non-cryopreserved hPSC-CMs (van den
Brink et al., 2020).
The reagents and techniques comprising
the workflow described here derive from in-
house development, as well as a variety of con-
temporary protocols and guidelines. The in-
clusion of KSR in CM Suspension and Freeze
media is likely to be beneficial to hPSC-CMs
by bolstering B-27 in terms of survival fac-
tors (e.g., insulin and transferrin), and increas-
ing the amount of protein via bovine serum
albumin (BSA), which among other things
will help to quench protease activity fol-
lowing dissociation with 10× TrypLE. Slow
dropwise resuspension as a way of avoiding
osmotic shock to hPSC-CMs immediately fol-
lowing thawing is noted as critical in sev-
eral protocols and papers (e.g., Breckwoldt
et al., 2017; NCardia, 2018; van den Brink
et al., 2020). RevitaCell is a pro-survival sup-
plement commonly used in hPSC culture to
avoid anoikis during single-cell passaging,
containing a Rho-associated kinase (ROCK)
inhibitor and anti-oxidant factors. The ap-
plication of RevitaCell or some other pro-
survival supplement for the first day fol-
lowing re-plating of hPSC-CMs by us and
others (Breckwoldt et al., 2017; van den Brink
et al., 2020) is partly based on observations by
Laflamme et al., whereby inclusion of a pro-
survival cocktail increased engraftment size
of hESC-CMs in rat hearts (Laflamme et al.,
2007). Although we have not rigorously com-
pared hPSC-CM recovery after re-plating with
or without RevitaCell, we would nonetheless Miller et al.
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recommend inclusion of some kind of pro-
survival supplement in the medium on the day
of thawing.
Viability and recovery of hPSC-CMs us-
ing this workflow should be comparable when
using other commercial kits, published dif-
ferentiation protocols, and CM maintenance
medium (e.g., from NCardia, Cellular Dynam-
ics, or Miltenyi) (Allen_Institute, 2018; Birket
et al., 2015; Burridge et al., 2014). However,
it is advised to follow manufacturer guidelines
where available and adjust media and condi-
tions to optimize processes. A small amount
of variability can also be expected. This can
derive from differences between hPSC lines,
differentiation protocols, the cellular compo-
sition (CMs vs. non-CMs) of individual dif-
ferentiation batches, as well as other technical
details such as reagent batches and individual
user technique. There are certain adjuncts to
the protocols that we have also observed as
potentially beneficial for cell viability and re-
covery although they have not been rigorously
tested. In particular–addition of DNase I dur-
ing dissociation with 10× TrypLE to reduce
clumping and increase viability; a higher cell
freezing density of >10 × 106 cells/ml and/or
a freezing volume <0.5 ml/vial to provide a
more consistent freezing rate, although there
is slightly conflicting data regarding this (see
Preininger et al., 2016). Furthermore, the use
of controlled rate freezing machines such as
ViaFreeze may also offer significant benefits;
however, this again would require further op-
timization, as well as an increased financial
outlay.
An alternative to the fast dissociation
protocol described here exists in the form
of a longer two-stage protocol. hPSC-CM
monolayers or 3D clusters are partially dis-
sociated slowly by incubating in collagenase
type I (Sigma) in PBS+/20% FBS or Lib-
erase (Roche) plus DNase I for 20-60 min,
followed by a quick final digestion with
trypsin-EDTA or TrypLE for 3-10 min (Berg
Luecke et al., 2019; Chen et al., 2015; Mills
et al., 2017). This protocol may confer one
advantage in reducing the total time exposed
to strong protease activity, which may be
beneficial in particular for 3D clusters due
to the increased density and gradient of
exposure to the dissociation solution. How-
ever, a strong protease step is still required,
and the workflow is more complex. Un-
fortunately to our knowledge there are no
available direct comparisons between the two
approaches.
Critical Parameters
There are several critical parameters in-
fluencing dissociation, cryopreservation, and
thawing of hPSC-CMs that can each be indi-
vidually addressed to maximize recovery of
cells. The dissociation time with 10× TrypLE
can be adjusted based on the cell density
and availability of a cell shaker, and will
vary based on the hPSC line, and differenti-
ation protocol and time point. Gentle initial
pipetting to dissociate the cells in TrypLE,
as well as handling in subsequent steps is
also important to avoid shear stress. Cell
clumping as a result of excessive cell death
and subsequent release of DNA and other
cellular debris can be reduced by using a cell
shaker during dissociation, reducing pipet-
ting, and including DNase I. Different hPSC
lines and differentiation protocols will exhibit
varying amounts of cell clumping. If it does
occur, use of a 70-100-μm cell strainer can
partially rescue the situation. A steady rate of
freezing is crucial to cryopreservation of all
cells, hence all parts of the protocol especially
equipment and freezing medium must be well
prepared and pre-cooled, and the process con-
ducted in a time-efficient manner. A fast thaw
combined with a slow regulated resuspen-
sion avoiding osmotic shock is also crucial
to maintaining viability when recovering
hPSC-CMs.
Troubleshooting
See Table 4 for troubleshooting possible
problems encountered during the protocols.
Understanding Results
In this article, we have described a simple
workflow for the dissociation, cryopreserva-
tion, and recovery of hPSC-CMs. We have also
investigated aspects of these protocols, includ-
ing the effects of differentiation day and cry-
opreservation media. We hope this will pro-
vide a benefit for users in standardizing and
simplifying hPSC-CM workflows, in order to
improve reproducibility in downstream appli-
cations.
A key parameter used in this report and
those discussed above is hPSC-CM viability.
We use trypan blue exclusion as an indicator
of viability throughout the workflow, i.e., how
many cells are degraded and/or apoptotic and
no longer exclude trypan blue. Viability can
also be assessed by immunostaining and flow
cytometry. The values derived from these two
methods can slightly differ, given the different
mechanism, sensitivity, and timing of the two
Miller et al.
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Table 4 Troubleshooting




• Cell line or
differentiation protocol
• Excessive pipetting
• Addition of DNase I (Stem Cell
Technologies) to TrypLE/dissociation solution
• Use cell shaker and/or increase TrypLE
incubation time by 1-4 min to improve
dissociation and reduce pipetting
• Following centrifugation and resuspension,
pass clumped cell suspension through 70-100-μm
cell strainer into a fresh Falcon tube, and gently





• Cell line or
differentiation protocol
• Wash twice with 2 ml PBS- per well before
dissociation
• Use cell shaker to improve dissociation
• If clumps detach whole, transfer into 50-ml
Falcon together with 3-6 ml TrypLE and place in
37°C water bath for 8-12 min until dissociated,
gently swirling every 2 min






• Increase TrypLE incubation time by 1-4 min
and reduce pipetting
• Reduce TrypLE incubation time by 1-4 min
and/or dilute TrypLE to 5-8× with PBS-
Poor functional
recovery after thawing




• Check reagent batches and expiry dates
• If cryostorage boxes use isopropanol, check
and replace with fresh. Check freezer
temperatures, ensure cold chain handling from
−80°C to liquid N2 is maintained, store cryovials
in vapor phase of liquid N2
procedures; however, in practice it is quicker
and cheaper to generate an indicative number
by trypan blue.
We observe a tendency to lose viability
with later days for initial dissociation of hPSC-
CMs (Fig. 3B). This may be due to the in-
crease in cell density and cell-cell junctions
that likely occurs with a longer period in dif-
ferentiation culture (Fig. 3A), requiring longer
incubation in TrypLE and/or more pipetting
to dissociate. A preference for dissociating
hPSC-CMs earlier to apply to more complex
3D cultures is emerging, as this may be ben-
eficial for their maturation and functional fi-
delity in these contexts due to a maturation
window which cells pass through soon after
lineage commitment (Breckwoldt et al., 2017;
Mills et al., 2017; Ronaldson-Bouchard et al.,
2018). Together these observations and trends
would suggest that dissociation and cryop-
reservation of hPSC-CMs at around day 14
of differentiation would be a good general
workflow for many hPSC-CM applications. It
should be noted; however, that for some appli-
cations this would then require a longer time in
culture subsequent to thawing and re-plating,
since older hPSC-CMs even in simple mono-
layer cultures exhibit a slightly more mature
transcriptional and functional profile (Kumar
et al., 2019), which may be important for cer-
tain assays. Interestingly, we have observed
a phenomenon whereby raised expression in
MLC2v (MYL2) can be seen at ∼day 21 fol-
lowing dissociation and re-plating of hPSC-
CMs at ∼day 14, with or without cryopreser-
vation (compare Fig. 3D and Fig. 5C), with
negligible expression of MLC2v at day 21
in parallel hPSC-CMs left un-split (data not
shown). This would suggest that initiation of a
more mature ventricular CM identity requires
dissociation and re-plating. This may be due
to space restriction in differentiation cultures
before dissociation and re-plating, or perhaps
because dissociation and re-plating permits in-
creased cell-cell junction and syncytia forma-
tion between hPSC-CMs.
In terms of differences between the four
media we have tested for cryopreservation of Miller et al.
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hPSC-CMs, the data presented here, as well
as our general observations indicate that they
are largely comparable despite markedly dif-
ferent formulations. This may be partly due
to the fact they all contain the same CPA
and are applied with an optimized workflow.
Our investigation does not eliminate the pos-
sibility that repeated, or more in-depth analy-
ses may reveal some differences, e.g., at the
metabolic or transcriptional level. However,
any such differences may also be temporary
given the brief period the cells are present
in cryopreservation media. That said, we ex-
cluded FBS/10% DMSO from downstream
functional analysis for several reasons. Al-
though it has a long standing as a basis for
cryopreservation medium, and is still used in
some protocols and by many groups, it suf-
fers from several drawbacks compared to the
other three media investigated here–it is not
the cheapest, it is the most likely to suffer from
batch variability and price fluctuations, some
effects on hPSC-CM function when included
in maintenance medium have been observed
(Dambrot et al., 2014), and it is more difficult
to convert to current good manufacturing prac-
tice (cGMP).
We have studied the applicability of four
common cryopreservation media in this re-
port but would like to note several other ob-
servations and options. Despite being by far
the most widely used CPA, it is acknowledged
that DMSO can have some detrimental effects
on cells in culture (Verheijen et al., 2019).
We compared 5% rather than 10% DMSO
in KSR- or FBS-based freezing media; how-
ever, found this resulted in poorer recovery
of hPSC-CMs and/or a slight negative im-
pact on TNNT2 expression (data not shown).
Similarly, we found BamBanker less good
for recovery of hPSC-CMs (data not shown),
as noted in Burridge et al. (2015). Other
media such as Synth-a-freeze, StemMACS
CryoBrew, and NutriFreeze may be viable
options for hPSC-CM cryopreservation but
require testing.
Conclusion
Application of this simple workflow should
allow cryopreservation of hPSC-CM batches
with a recovery of up to 70% with no special-
ized or expensive equipment. The four differ-
ent cryopreservation media tested here appear
to give similar results in terms of critical pa-
rameters for hPSC-CM recovery and function.
Cost and compatibility of media components
then need to be considered for the downstream
application of cells.
Time Considerations
Basic Protocol 1: ∼30 min preparation, 45-
60 min handling.
Basic Protocol 2: ∼60 min preparation (in-
cluding pre-coating of plates), ∼45 min han-
dling.
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